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Abstract
Purpose—Sensory peripheral neuropathy is a common and sometimes debilitating toxicity
associated with paclitaxel therapy. This study aims to identify genetic risk factors for development
of this toxicity.
Experimental Design—A prospective pharmacogenetic analysis of primary breast cancer
patients randomized to the paclitaxel arm of CALGB 40101 was used to identify genetic
predictors of the onset and severity of sensory peripheral neuropathy. A genome-wide association
study in 855 subjects of European ancestry was performed and findings were replicated in
additional European (n = 154) and African American (n = 117) subjects.
Results—A single nucleotide polymorphism in FGD4 was associated with the onset of sensory
peripheral neuropathy in the discovery cohort (rs10771973; HR, 1.57; 95% CI, 1.30–1.91; P = 2.6
× 10−6) and in a European (HR, 1.72; 95% CI, 1.06–2.80; P = 0.013) and African American (HR,
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1.93; 95% CI, 1.13-3.28; P = 6.7 × 10−3) replication cohort. There is also evidence that markers in
additional genes, including EPHA5 (rs7349683) and FZD3 (rs10771973), were associated with the
onset or severity of paclitaxel-induced sensory peripheral neuropathy.
Conclusions—A genome-wide association study has identified novel genetic markers of
paclitaxel-induced sensory peripheral neuropathy, including a common polymorphism in FGD4, a
congenital peripheral neuropathy gene. These findings suggest that genetic variation may
contribute to variation in development of this toxicity. Validation of these findings may allow for
the identification of patients at increased risk of peripheral neuropathy and inform the use of an
alternative to paclitaxel and/or the clinical management of this toxicity.
Keywords
paclitaxel; peripheral neuropathy; breast cancer; pharmacogenetics; genome-wide association
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Introduction
Paclitaxel is a useful microtubule stabilizing agent with efficacy in the treatment of many
cancers. It is effective for the treatment of breast cancer in the metastatic, adjuvant and
neoadjuvant settings (1, 2). Sensory peripheral neuropathy remains a significant issue in the
clinical utility of this agent. More than 50% of patients experience some degree of sensory
peripheral neuropathy during their course of paclitaxel treatment, with 5–30% experiencing
Grade 3 or 4 toxicity (3, 4). Paclitaxel-induced sensory peripheral neuropathy is dose-,
treatment schedule- and infusion-time dependent (3). Cumulative dose is a significant
predictor of sensory peripheral neuropathy, as is underlying diabetes and concurrent or
previous administration of other drugs associated with this toxicity. A recent study suggests
that mild to moderate symptoms of sensory peripheral neuropathy can persist for up to two
years following completion of paclitaxel treatment (5). Long-term neuropathy is particularly
concerning for patients with primary breast cancer, such as those evaluated in the current
study, since more than 80% will be long-term survivors whose quality of life will be
compromised. Significant sensory peripheral neuropathy during paclitaxel treatment can
lead to dose reductions and treatment suspension, possibly resulting in sub-optimal disease
treatment and the potential for an increased likelihood of relapse. A predictive marker for
this dose-limiting toxicity would enable studies to identify if an individualized assessment of
adverse event risk could be useful in the clinical decision-making process. It could also
provide a possible target for therapeutic interventions.
Substantial inter-individual differences in the prevalence, reported and objective severity,
and onset of peripheral neuropathy is consistent with an underlying genetic susceptibility to
this toxicity. CALGB 40101 is a Phase III randomized study comparing cyclophosphamide
and doxorubicin versus single agent paclitaxel as adjuvant therapy for breast cancer patients
at relatively low risk for relapse. In addition, the study compared short versus longer therapy
of each regimen as a 2×2 factorial design. A pharmacogenetic companion study (CALGB
60202) was included in this trial to prospectively evaluate germline determinants of
interindividual differences in response and toxicity. An initial analysis of treatment outcome
in CALGB 40101 has shown no difference in response between the four and six cycle
treatment arms (6); additional analyses of response await complete follow-up data. The goal
of this present study was to identify genetic markers predictive of sensory peripheral
neuropathies in the paclitaxel treatment arm of CALGB 40101 and to further our
understanding of the underlying mechanism of injury and repair. Herein we report the
results of a genome-wide association study (GWAS) of 1,040 paclitaxel treated women to
identify novel germline susceptibility loci associated with the development of sensory
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peripheral neuropathies. This represents the largest prospective breast cancer
pharmacogenetic study of paclitaxel treatment toxicities to date and provides a paradigm for




All study participants were enrolled in CALGB 40101 and gave their additional consent to
participate in the pharmacogenetic companion study (CALGB 60202). CALGB 40101 was
open from May 15, 2002 until July 30, 2010. The final total accrual was 3,873 patients.
Patients eligible for the treatment protocol were females with histologically confirmed
invasive carcinoma of the breast and zero to three axillary nodes positive for cancer. ECOG
performance status of 0–1, adequate organ function, and absence of CHF or myocardial
infarction in the previous six months were required. Enrollment was required within 84 days
of breast surgery (either modified radical mastectomy or lumpectomy) and treatment began
within seven days of registration. Patients with locally advanced, inflammatory or metastatic
breast cancer or involvement of dermal lymphatics were ineligible. Patients were disease-
free from any prior malignancies for at least five years. Previous trastuzumab, chemotherapy
or hormonal therapy, with the exception of tamoxifen, for the current malignancy was not
permitted nor was anthracycline treatment for any previous disease. Patients who received
tamoxifen or any other selective estrogen receptor modulators (SERM) for prevention or
other indications (e.g. osteoporosis) were eligible. Treatment with tamoxifen, other SERMs
or exogenous hormones (e.g. hormone replacement therapy, oral contraceptives, raloxifene)
was discontinued prior to enrollment. Trastuzumab was recommended for patients with
HER2 positive disease. Patients could also enroll in adjuvant studies of bisphosphonates or
hormonal therapies (e.g. ovarian suppression concurrent with chemotherapy). All patients
provided written informed consent for both the treatment and companion protocols that met
state, federal and institutional guidelines.
Treatment
Patients were randomly assigned with equal probability to four or six cycles of
cyclophosphamide/doxorubicin (AC) or paclitaxel. A full description of the study design is
included in a recent publication describing the initial analysis of treatment response (6). The
first 570 patients were treated with AC every three weeks, or paclitaxel weekly for 12 or 18
weeks. Thereafter both regimens were administered every two weeks for four or six cycles.
Pharmacogenetic samples were collected only from patients enrolled on the every two week
regimens who received dose dense paclitaxel for four or six cycles. Paclitaxel was given
over three hours at 175 mg/m2 when given every two weeks. The six cycle treatment arms
for both drugs were closed after enrolling 3,172 patients. Arms were stratified by
menopausal, estrogen receptor (ER), progesterone receptor (PgR) and HER2 status. Patient
demographics are shown in Table 1. Premedication recommendations for the initial dose
were 12.5 – 50 mg diphenhydramine and either 50 mg ranitidine, 300 mg cimetidine, or 20
mg famotidine administered IV 30 – 60 minutes prior to paclitaxel. Dexamethasone was
given as a 10 mg intravenous dose within 60 minutes of paclitaxel or alternatively, as a 10
mg or 20 mg oral dose more than one hour prior to paclitaxel. To facilitate the 14 day dosing
schedule, filgrastim was recommended on days 3–10 of each cycle (5 µg/kg rounded to
either 300 or 480 µg). Sargramostim (250–500 µg/m2, days 3–10) or pegfilgrastim (6 mg sc,
24–36 hours after paclitaxel) could be used in place of filgrastim. The treating physician
could omit G-CSF treatment when confident neutrophils would recover within 14 days,
however if treatment could not be delivered on schedule then a G-CSF was required in
subsequent cycles. Erythropoetin was permitted at the discretion of the treating physician.
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Patients positive for HER2 by either IHC 3+ staining or gene amplification by FISH could
initiate adjuvant trastuzumab concurrent with paclitaxel (weekly administration) or at the
completion of paclitaxel (weekly or every 3 weeks). Weekly trastuzumab consisted of a 4
mg/kg intravenous loading dose followed by weekly doses of 2 mg/kg and the three week
schedule of a loading dose of 8 mg/kg and 6 mg/kg every three weeks for a total duration of
one year.
Genotyping and Quality Control
A summary of the steps included in sample and single nucleotide polymorphism (SNP)
quality control and in principal components analysis (PCA) is illustrated in Supplemental
Figure 1. A total of 1,040 paclitaxel-treated patients with informed consent and a DNA
sample (obtained from peripheral blood) available as of July 1, 2009 were included in the
primary study. Genomic DNA was genotyped using the HumanHap610-Quad Genotyping
BeadChip (Illumina, CA, USA) which interrogated 592,532 SNPs. Subjects with call rates
<0.98 (n=5) or with suboptimal genotype clustering performance (n=1) were excluded
followed by reassessment of genotypes within the remaining subjects. SNPs with call rates
<0.95, poor genotype clustering performance, >1 replicate or Mendelian discordance,
relative minor allele frequency (MAF) < 0.005, non-diploid (e.g. Y or mitochondrial
chromosomes) or deemed unreliable by Illumina (n=4,106; Tech Note: Infinium®
Genotyping Data Analysis, 2007) were excluded, leaving 572,745 SNPs. Identity-by-descent
(IBD) analysis verified the absence of closely related individuals (proportion IBD > 0.15)
and identified one unintended duplicate pair which was removed and later confirmed to be
due to a DNA plating error (PLINK version 1.07) (7). Evaluation of X-chromosome
heterozygosity identified three genetic males which were also removed and similarly
confirmed to be due to a DNA plating error (8). PCA as implemented by EIGENSOFT
version 3.0 was used to visualize the genetic ancestry of the 1,029 individuals passing QC
(9). PCA was performed using genotypes from study subjects combined with genotypes of
unrelated individuals from the HapMap Project representing Northwest European (CEU,
n=73), African (YRI, n=77) and Chinese (CHB, n=75) ancestries and genotyped using the
same platform by Illumina (Supplemental Figure 2) (10). To address the potential bias
arising from population stratification, we chose to focus our primary analysis on individuals
of Northern European descent. A second PCA was performed using only the 1,029 study
subjects. Mean values for the first three eigenvectors within all patients self-declaring
“White” race and “Non-Hispanic” ethnicity were determined. “Genetic Northwest
Europeans” (herein called Europeans) were defined as individuals with each of their first
three eigenvectors within two standard deviations of each mean value irrespective of self-
declared race and ethnicity. A total of 859 individuals were identified and identical results
were obtained when repeated with the inclusion of HapMap individuals (not shown). These
859 individuals were the focus of the primary analysis (Supplemental Figure 2).
Imputation of genotypes was performed within the 859 Europeans using MACH 1.0 (11)
and reference haplotypes from unrelated CEU individuals from either HapMap (r22) or the
1000 Genomes Project (June 2010 release). Prior to imputation, study genotypes were more
stringently filtered and limited to autosomal SNPs with MAF ≥ 0.01 and exact Hardy-
Weinberg P-values ≥ 0.001 in control subjects. To address any potential stranding
inconsistencies between study genotypes and the reference haplotypes, all symmetric SNPs
(A/T or C/G) with MAF > 0.40, and therefore difficult to resolve, were removed leaving
548,596 and 547,465 SNPs for imputation using the HapMap and 1000 Genomes reference
haplotypes, respectively. Imputed SNPs with MAF < 0.01 or R2 < 0.5 were excluded.
Genotyping within the replication cohorts (described below) was performed using TaqMan®
Allelic Discrimination assays (Applied Biosystems) and individual assays are shown in
Supplemental Tables 1 and 2.
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One hundred fifty nine self-declared “White” individuals with either “Non-Hispanic” or
“Unknown” ethnicity who enrolled in the CALGB 40101 pharmacogenetic companion study
subsequent to the genotyping of the original 1,040 subjects were used as a replication
cohort. Within the discovery set, these criteria accurately identified 98.7% of the 859
Europeans with a false-positive rate of 2.4%. An additional 100 individuals of African
ancestry were also identified from within the group of 1,029 individuals passing sample
quality control. African ancestry was defined using individuals who self-declared “Black/
African American” race with either “Non-Hispanic” or “Unknown” ethnicity. Any
individual with their first three eigenvectors within three standard deviations of each
eigenvector mean value were considered to be of African descent. These self declared race/
ethnicity criteria identified 94.2% of individuals with African ancestry and incorrectly
identified 2.0%. The final African American replication cohort consisted of the 100 patients
of African descent with genome-wide data and an additional 20 self-declared “Black/African
American” individuals with either “Non-Hispanic” or “Unknown” ethnicity who enrolled
after the original genotyping.
Statistical Analysis
The primary objective was the identification of SNPs associated with the occurrence of
sensory peripheral neuropathy. The analyses were carried out using two complementary
endpoints: 1) the cumulative dose level triggering the first grade 2 or higher treatment
related sensory peripheral neuropathy episode and 2) the maximum observed treatment-
related sensory peripheral neuropathy grade. The adverse events were graded according to
the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE)
version 2.0. The timing of sensory peripheral neuropathy was assessed with a time to event
approach where an event was defined as the first incidence of a grade 2 or higher neuropathy
and time as the cumulative paclitaxel exposure (mg/m2). For patients not experiencing any
event, the total study paclitaxel drug exposure was used. These patients are effectively right-
censored at the cumulative dose level. The marginal associations were tested using the Cox
score test (12). The severity of sensory peripheral neuropathy, defined as the maximum
grade neuropathy observed during paclitaxel treatment or within 30 days following the last
dose, was evaluated using ordinal logistic regression. Cumulative dose (mg/m2) was log
transformed and incorporated into the ordinal regression model. For both cases, the marginal
null sampling distribution was approximated using asymptotics. These analyses were
powered for an additive genetic model. To minimize Type I error due to sparseness, SNPs
within the European discovery set were constrained to relative MAF ≥ 1% and the
observation of a minimum of two minor allele homozygous genotypes leaving 521,600
evaluable SNPs. Imputed genotypes were represented as allele dosages bound between 0.0
and 2.0. All analyses were performed using the R statistical environment version 2.12 with
the cumulative dose to event and ordinal analyses implemented using functions from the
survival and MASS extension packages (13–16). Quantile-quantile plots of the marginal
asymptotic P-values were evaluated for potential remaining population stratification or
inflation of significance levels. Each SNP with a marginal P-value ≤ 10−5 was evaluated
further for potential errors by checking its MAF (vs. HapMap), Hardy Weinberg
Equilibrium (HWE) within unaffected subjects, and potentially informative missing rates;
they were also visually inspected for genotype clustering performance.
Based on the combined results of the time to event and ordinal regression analyses of the
859 European patients, a replication plan delineating SNPs, regression model, genetic model
(the most plausible model suggested from Kaplan-Meier estimates) and effect direction for
one-sided testing was drafted a priori to any data collection within the replication cohorts.
Three SNPs from the genes FZD3, EPHA5 and FGD4 (rs7001034, rs7349683, and
rs10771973) were selected for replication based on marginal significance levels, biological
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plausibility and estimated effect size (as detailed in the Results). An additional ten SNPs
with P-values < 10−5 and/or previously implicated in congenital sensory peripheral
neuropathies (NDRG1) were also evaluated with the specified limitation of being
constrained to exploratory analyses. Genotypes for the FZD3 SNP rs7001034 were captured
indirectly using a proxy SNP (rs7833751; R2 = 1.0 CEU HapMap r27) due to the absence of
acceptable TaqMan assays to evaluate the locus directly. Due to the impracticality of
capturing the FZD3 linkage disequilibrium (LD) block to the same extent as the European
group, this locus was not evaluated in the African ancestry replication group. Direct
sequencing was used to capture the FGD4 rs10771973 genotypes within the replication
cohorts. To limit the overall Type I error rate for the validation study at the one-sided 0.05
level, we tested each of the three SNPs at the marginal 0.01 level. Since the FGD4 locus
replicated in both populations and there are significant differences in LD structure between
the European and African American populations, an additional four coding region SNPs
were chosen from the ~30 kb LD block containing rs10771973 to further extend this finding.
In addition, to evaluate the independence of the identified association in rs10771973, the
time to event analysis was repeated with rs10771973 as a covariate. This analysis was
conducted using the R extension package GenABEL (13). A haplotype based association
test was also conducted for the three genes containing the top hits (EPHA5, FZD3 and
FGD4), using all genotyped SNPs within 100 kb of the transcription start and stop sites for
each gene. Phase for each SNP set was estimated using fastPHASE v 1.1 in all samples
combined (17). Haplotype block boundaries using the method of Gabriel et al. were
generated in Haploview v4.2 using HapMap v3 r2 CEU samples (18). For each haplotype
block that included an allele with a per SNP association signal of < 10−3, individual
haplotypes were extracted from fastPHASE output, and haplotypes with frequency less than
5% were combined. Association with outcome was analyzed on a per haplotype basis using
time to event or maximum grade as described above.
Results
Of the 859 individuals with European ancestry randomly assigned to paclitaxel treatment,
four withdrew prior to study treatment and were therefore excluded (Supplemental Figure
1). Patient characteristics of the CALGB 40101 paclitaxel treatment arm, the genotyped
samples, and the discovery and replication cohorts are listed in Table 1. The menopausal,
ER, PgR and HER2 status, and the assigned number of cycles were not different between the
genotyped paclitaxel cohort and the European discovery cohort. The genotyped sample was
also representative of all patients randomized to paclitaxel treatment in CALGB 40101. One
exception is a fewer number of samples from the six cycle paclitaxel arm in the European
replication cohort, which reflects the early closure of the six cycle arm and the later study
enrollment of this group of patients. Peripheral sensory neuropathy was the major dose
limiting toxicity in the paclitaxel arm and the distribution of toxicity grades within the 855
patients in the primary analysis, stratified for number of treatment cycles assigned, is shown
in Table 2. Sensory peripheral neuropathy was dose dependent with 17% of the patients
randomized to four cycles of paclitaxel experiencing a grade 2 or greater event as compared
to 33% of those randomized to six cycles of treatment. The cumulative incidence of sensory
peripheral neuropathy was similar between the entire cohort randomized to paclitaxel
treatment and the discovery set (Supplemental Figure 3), and between the discovery set and
both replication groups (data not shown). There was no effect of age on cumulative dose
triggering a grade 2 or greater peripheral neuropathy event (data not shown).
Among the SNPs analyzed in the GWAS for association with the initial onset of sensory
peripheral neuropathy, none reached genome-wide significance although seven had a
marginal significance level of P < 10−5 (Table 3 and Supplemental Figure 4). Inspection of
the quantile-quantile plot of the marginal P-values (Supplemental Figure 5A) indicates the
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absence of any remaining population substructure (λ = 1.01). Of these top SNPs, biological
relevance was apparent for polymorphisms in EPHA5 (rs7349683; per allele HR, 1.63; 95%
CI, 1.34 – 1.98; P = 9.6 × 107; Figure 1A) and FGD4 (rs10771973; per allele HR, 1.57; 95%
CI, 1.30 – 1.91; P = 2.6 × 106; Figure 1B). EPHA5 encodes an ephrin receptor gene
implicated in the process of neuronal regeneration following nerve injury and FGD4
encodes a Rho-GTPase guanine nucleotide exchange factor previously implicated in
congenital peripheral neuropathies (19–22). The FGD4 (Table 3; Supplemental Figures 6A
and 6B) and EPHA5 (Table 3; Supplemental Figures 7A and 7B) SNPs were tested in
replication cohorts and association for the former was confirmed in both the European and
African American samples (Europeans: rs10771973; per allele HR, 1.72; 95% CI, 1.06 –
2.80; P = 0.013; African Americans: rs10771973; per allele HR, 1.93; 95% CI, 1.13 – 3.28;
P = 6.7 × 10−3). Considering the high minor allele frequency of this risk allele in Europeans,
42% of patients are expected to have a 1.6-fold increased risk and 9% a 2.6-fold increased
risk of peripheral neuropathy; in African Americans (MAF 17%) the increased risk is 1.9-
and 3.7-fold, respectively. Inspection of the Kaplan-Meier genotype stratified time to
neuropathy distributions suggests that an allele dose effect assumption for FGD4
rs10771973 is appropriate (Figure 1B).
No haplotypes in FGD4 or EPHA5 showed stronger association with time to sensory
peripheral neuropathy than the single SNP analyses in these regions (data not shown). After
conditioning the time to event analysis on rs10771973, no other genotyped markers at the
FGD4 locus showed association with time to peripheral neuropathy (data not shown). Using
imputation to infer additional untyped markers and visualizing the linkage disequilibrium
(LD) structure within the HapMap CEU population revealed a ~30 kb region of high LD
within the FGD4 locus showing a strong and reproducible association with the onset of
sensory peripheral neuropathy (Supplemental Figure 8). Approximately 16 SNPs are
strongly linked (R2 ≥ 0.80) with rs10771973, five of which are synonymous variants within
the coding region.
Ordinal logistic regression analyses were used to identify SNPs associated with the severity
of sensory peripheral neuropathy. Four SNPs were associated with toxicity grade with a
significance level of P < 1 × 10−5 (Table 4 and Supplemental Figure 4). As with the Cox
analysis, a quantile-quantile plot of the normalized marginal P-values (Supplemental Figure
5B) suggests the absence of any remaining population substructure (λ = 0.986). A SNP
within the Frizzled 3 homolog WNT signaling receptor gene (FZD3) met the threshold of
genome-wide significance (rs7001034; P = 3.1 × 10−9; OR, 0.57; 95% CI, 0.48 – 0.69) and
demonstrated a clear relationship between allele dosage and sensory peripheral neuropathy
grade (Figure 2). However, none of these top SNPs from the ordinal regression analysis
replicated in either the European or African American populations (Table 4).
Discussion
A small subset of patients exposed to paclitaxel have significant and occasionally protracted
neuropathy that has a major impact on quality of life. If we could prospectively identify
these patients prior to administration of paclitaxel, they might be otherwise equally well
served with alternative non-paclitaxel containing regimens. Using a genome-wide
association study of CALGB 40101, we have identified several genetic loci associated with
onset or severity of paclitaxel-induced sensory peripheral neuropathy. One of these novel
markers associated with early-onset paclitaxel-induced sensory peripheral neuropathy
(FGD4, rs10771973) was replicated in both Europeans and African Americans and resides
within a gene with a clearly established role in the hereditary peripheral neuropathy Charcot-
Marie-Tooth disease (CMT). These findings will inform studies to test the application of
genetic markers for optimization of paclitaxel selection, dosing and adverse event
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management. Several features of the study design and analysis support the robustness of our
findings, including the prospective design, a large cohort of patients with primary breast
cancer who are chemotherapy naïve and treated with single agent paclitaxel, careful
collection of sensory peripheral neuropathy and covariate data, strict censoring for dose and
cycle reductions for other adverse reactions and preexisting neuropathy, and the use of
cumulative dose to the initial incidence of Grade 2 toxicity to account for the established
effect of total drug exposure on sensory peripheral neuropathy.
The current finding that FGD4 plays a role in the development of paclitaxel-induced sensory
peripheral neuropathy and/or the repair response of peripheral nerves following paclitaxel
injury is consistent with the known functions of the gene. FGD4 encodes for the protein
FGD1-related F-actin binding protein (Frabin) and previous studies have shown specific
point mutations in FGD4 can cause the congenital peripheral neuropathy Charcot-Marie-
Tooth disease (CMT4H) (21–24). The disease is characterized by a slow progressive
demyelination of peripheral sensory and motor neurons accompanied by distal muscle
weakness and atrophy, sensory loss, hyporeflexia and skeletal deformity (25). Paclitaxel-
induced peripheral neuropathy shares some of these characteristics, including sensory loss
and secondary demyelination (26–28). Frabin is a guanine nucleotide exchange factor for
cdc42, a Rho-GTPase that regulates cellular morphogenesis, including myelination. Several
hypotheses have been proposed to explain how mutations in FGD4 might lead to
demyelinating CMT4H disease, including disruption of the actin/microtubule cytoskeleton,
loss of c-Jun-NH-terminal kinase (JNK) activation signals, and disruption of
phosphoinositide signaling pathways, all of which could affect Schwann cell myelination
and/or the bidirectional communication between Schwann cells and axons (21).
The observed association between the FGD4 SNP rs10771973 and paclitaxel-induced
sensory peripheral neuropathy is consistent with the hypothesis that common FGD4
polymorphisms subtly affect the development and/or maintenance of Schwann cell function.
In this case, carriers of common FGD4 polymorphisms would have pre-existing subclinical
abnormalities and a predisposition for toxicity. This is supported by increased risk for
paclitaxel-induced sensory peripheral neuropathy in asymptomatic patients with diabetes,
previous platinum drug exposures and alcohol use (3) and early Schwann cell activation in
response to paclitaxel administration (29). Alternatively, FGD4 polymorphisms could lead
to impaired repair processes such as Schwann cell remyelination and/or axonal regeneration
after paclitaxel exposure. Genetic variation in FGD4 could also directly affect the response
of Schwann cells to axonal injury via its ability to activate JNK (30). A neuronal protective
role for activated JNK in cultured dorsal root ganglion cells exposed to oxaliplatin has been
reported (31). Whether changes in frabin activity or expression lead to a decreased neuronal
regenerative capacity and/or an increased sensitivity to paclitaxel-induced sensory peripheral
neuropathy requires further study. Interestingly, FGD4 was identified through a genome-
wide siRNA screen in lung cancer cell lines as a paclitaxel chemosensitizer. The
chemosensitizing properties of FGD4 are related at least in part to its ability to prevent
mitotic progression (32). Whether a similar mechanism is involved in the repair response to
paclitaxel-induced peripheral neuropathy is unknown.
The FGD4 rs10771973 SNP is located in the intronic region and is in tight LD with a
number of other SNPs. Computational analysis of the genomic region surrounding this SNP
found that rs10771972, another intronic SNP in high LD with rs10771973 in both the
European and African populations, is predicted to alter conserved transcription factor
binding sites for Myc-Max and USF (data not shown). One could speculate that disruption
of either one or both of these transcription factor binding sites in patients carrying the
rs10771973 SNP could lead to altered expression and therefore function of FGD4/Frabin.
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The other two top hits from the genome-wide analysis are also of potential interest for the
paclitaxel-induced sensory peripheral neuropathy phenotype. In the time to toxicity analysis,
the most significant SNP was in EPHA5, which encodes for an ephrin receptor involved in
axonal guidance and regeneration following injury. Recent studies have shown that in mice
EphA5 mRNA is rapidly upregulated in response to a sciatic nerve lesion (20), and that
EphA5 signaling during synaptogenesis is transduced via cdc42 (19), the Rho-GTPase
involved in Frabin signaling. A common SNP in FZD3 reached genome-wide significance in
the ordinal analysis. FZD3 encodes a Wnt receptor with reported roles in neurite outgrowth
(33). In light of the biological relevance of EPHA5 and FZD3 and the limited size of the
replication cohorts available for these studies, it will be necessary to further explore the role
of these two genes in larger populations of paclitaxel-treated patients. Additional studies are
also warranted for other top hits, including rs2233335 in the N-myc Downstream-Regulated
Gene 1 (NDRG1; Supplemental Table 1). Rare mutations in NDRG1 are also associated
with a different subtype of CMT (CMT4D) (34).
Until the availability of genome-wide approaches for identifying genetic predictors of
paclitaxel-induced peripheral neuropathy, candidate gene approaches focused mostly on
drug metabolizing enzymes and transporters implicated in paclitaxel exposure. These
candidate gene studies yielded no replicated associations of SNPs with paclitaxel-induced
sensory peripheral neuropathy, and most were complicated by a very small number of
subjects, a retrospective analysis of toxicity, and chemotherapy with multiple agents (35–
38). In the current analysis, no significant associations were observed for any SNPs residing
in candidate genes known to influence paclitaxel exposure (Supplemental Table 3),
providing further evidence that factors contributing to the function and repair of peripheral
nerves are more important than alterations in paclitaxel pharmacokinetics for determining
genetic susceptibility to this toxicity. Interestingly, recent analyses of peripheral neuropathy
induced by treatment with bortezomib, thalidomide and vincristine have provided evidence
that genes involved in repair mechanisms, inflammation, peripheral nervous system
development and mitochondrial dysfunction could influence an individual patient’s risk of
developing toxicity (39–42). However there was no overlap of implicated genes with the
current study (Supplemental Table 3), suggesting that the mechanisms underlying this
common toxicity might be drug specific.
To assess the potential translational implications of this finding to clinical practice, we
estimated the cumulative dose level triggering an event for each FGD4 rs10771973
genotype. Considering the data in Figure 1B, to control the probability of experiencing a
neuropathy event at a critical threshold of 33%, the tolerated cumulative dose level for
patients with two copies of the risk allele is 710 mg/m2. The corresponding expected critical
dose level for patients with one copy of the risk allele is increased to 877 mg/m2. Patients
with no copies of the risk allele are expected to tolerate >1047 mg/m2, corresponding to the
full dose of paclitaxel for six cycles. If these thresholds are prospectively validated and
further refined in follow-up studies, they may be used to estimate tolerable dose levels based
on genotype and to tailor the treatment regimen.
While this pharmacogenetic study has several advantages over previous studies on paclitaxel
pharmacogenetics, including a large cohort of treatment naïve patients receiving single agent
paclitaxel and a genome-wide approach to discovery, several limitations also exist. The most
significant limitation is the sole use of the NCI-CTC for assessment of sensory peripheral
neuropathy. It is widely recognized that detailed patient-reported symptom data and a
quality of life assessment more accurately describes this phenotype and that physician
reported NCI-CTC grading underreports peripheral neuropathy (43–45). However, it
remains difficult to apply these techniques across the multiple sites and large sample sizes
required for sufficient power for pharmacogenetic analyses. In a recent Phase III study of
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1,060 women treated with taxanes, the Patient Neurotoxicity Questionnaire and the
Functional Assessment of Cancer Therapy-General were administered to only the first 300
patients in the study (46). The only use of patient-reported toxicity data and symptom
measurements for pharmacogenetic analysis of taxane peripheral neuropathy is limited by
the very small sample size of the study (38). While it will be important in follow-up studies
to validate these findings using additional instruments, it should be noted that despite its
limitations the NCI-CTC scores are widely accepted for primary evaluation of treatment
toxicity in large Phase III studies such as CALGB 40101. A second limitation of the current
study is the small sample size of the replication cohorts, a common issue confronting almost
all pharmacogenetic studies (47).
In summary, our findings support the use of prospective pharmacogenetic analyses of well
phenotyped data sets collected under controlled clinical trial settings and unbiased genome-
wide genetic approaches for the identification of novel genes involved in drug efficacy and
toxicity. Using a prospective design for validation and replication and a well-controlled
single agent clinical study we have identified a SNP in FGD4 associated with increased risk
of developing paclitaxel-induced sensory peripheral neuropathy. The involvement of FGD4
in Charcot-Marie Tooth disease, a congenital peripheral neuropathy, provides strong
evidence for the biological significance of this finding. The fact that a common FGD4 SNP
is associated with an increased risk of paclitaxel-induced sensory peripheral neuropathy in
patients with both European and African ancestry makes it of potentially broad clinical
significance. Additional SNPs in EPHA5 and FZD3 were also identified as potential risk
factors for the onset and severity of sensory peripheral neuropathy. Additional samples for
extension and validation of these findings are currently being collected in ongoing CALGB
clinical trials of paclitaxel in the setting of metastatic breast cancer.
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Paclitaxel is widely used in the treatment of many cancers, including breast cancer.
Treatment with paclitaxel is often limited by the development of peripheral neuropathies
which can significantly impact a patient’s quality of life. Biomarkers for the prediction of
paclitaxel-induced peripheral neuropathy could be used to optimize the use of paclitaxel.
A genome-wide genotyping approach in women receiving single agent paclitaxel as
adjuvant therapy for breast cancer identified several novel genetic loci implicated in
paclitaxel-induced sensory peripheral neuropathy. In particular, a common genetic
variant in FGD4, a causal gene for the congenital peripheral neuropathy Charcot-Marie-
Tooth Disease, was associated with increased onset of neuropathy in both Europeans and
African Americans. This variant and others identified in these studies could be validated
as genetic predictors of paclitaxel-induced sensory peripheral neuropathy. The genetic
variants identified in these studies will also lead to investigations into novel pathways for
this common chemotherapy-induced toxicity.
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Figure 1. The EPHA5 rs7349683 C>T and FGD4 rs10771973 G>A polymorphisms are associated
with an increased probability of developing paclitaxel-induced Grade 2 or greater sensory
peripheral neuropathy
The probability of the first instance of Grade 2 or greater neuropathy as a function of
cumulative paclitaxel dose (corrected for body surface area) is shown for each genotype.
Results are shown for A) rs7239683 (per allele HR = 1.63; 95% CI 1.34 – 1.98; P = 9.6 ×
10−7) and B) rs10771973 (per allele HR, 1.57; 95% CI, 1.30 – 1.91; P = 2.6 × 10−6) in the
discovery set. The number of individuals with each genotype is noted in parentheses.
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Figure 2. Association of FZD3 SNP rs7001034 with sensory peripheral neuropathy
The minor allele frequency of rs7001034 in the European discovery cohort is expressed as a
function of maximal grade of sensory peripheral neuropathy in 855 individuals.
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